Ribavirin augments doxorubicin's efficacy in human hepatocellular carcinoma through inhibiting doxorubicin-induced eIF4E activation.
about
Ribavirin augments doxorubicin's efficacy in human hepatocellular carcinoma through inhibiting doxorubicin-induced eIF4E activation.
description
2017 nî lūn-bûn
@nan
2017年の論文
@ja
2017年学术文章
@wuu
2017年学术文章
@zh-cn
2017年学术文章
@zh-hans
2017年学术文章
@zh-my
2017年学术文章
@zh-sg
2017年學術文章
@yue
2017年學術文章
@zh
2017年學術文章
@zh-hant
name
Ribavirin augments doxorubicin ...... icin-induced eIF4E activation.
@en
Ribavirin augments doxorubicin ...... icin-induced eIF4E activation.
@nl
type
label
Ribavirin augments doxorubicin ...... icin-induced eIF4E activation.
@en
Ribavirin augments doxorubicin ...... icin-induced eIF4E activation.
@nl
prefLabel
Ribavirin augments doxorubicin ...... icin-induced eIF4E activation.
@en
Ribavirin augments doxorubicin ...... icin-induced eIF4E activation.
@nl
P2093
P2860
P356
P1476
Ribavirin augments doxorubicin ...... bicin-induced eIF4E activation
@en
P2093
P2860
P356
10.1002/JBT.22007
P50
P577
2017-11-07T00:00:00Z